CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8,853 enrolled
Drug / intervention
Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03724877
NCT03724877N/ACompleted
CompareCT.gov

Comparative Effectiveness of Triple Therapy in COPD: A New-user Cohort Study

Boehringer Ingelheim·observational·Posted Oct 30, 2018·Updated Dec 3, 2019

In Brief

An observational study evaluating Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS) and Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 8,853 participants across 1 site.

Detailed Summary

To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with a LABA-LAMA combination on the risk of COPD exacerbation and the safety on the incidence of community acquired pneumonia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 30, 2018
Enrollment StartNov 10, 2018
Primary CompletionNov 12, 2018
TodayJul 2, 2026
Enrollment to primary: 2 daysPosted 7.7 years ago

Interventions

Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)drug

(LABA-LAMA-ICS)

Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)drug

(LABA-LAMA)